Mario I Fernandez

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/681448/publications.pdf

Version: 2024-02-01

33 papers	2,315 citations	304743 22 h-index	395702 33 g-index
33 all docs	33 docs citations	33 times ranked	2146 citing authors

#	Article	IF	Citations
1	Lymphovascular Invasion Predicts Clinical Outcomes in Patients With Node-Negative Upper Tract Urothelial Carcinoma. Journal of Clinical Oncology, 2009, 27, 612-618.	1.6	260
2	Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World Journal of Urology, 2017, 35, 379-387.	2.2	260
3	Impact of Lymph Node Dissection on Cancer Specific Survival in Patients With Upper Tract Urothelial Carcinoma Treated With Radical Nephroureterectomy. Journal of Urology, 2009, 181, 2482-2489.	0.4	186
4	Comparison of Oncologic Outcomes for Open and Laparoscopic Nephroureterectomy: A Multi-Institutional Analysis of 1249 Cases. European Urology, 2009, 56, 1-9.	1.9	161
5	Impact of Tumor Location on Prognosis for Patients with Upper Tract Urothelial Carcinoma Managed by Radical Nephroureterectomy. European Urology, 2010, 57, 1072-1079.	1.9	155
6	Tumour Necrosis Is an Indicator of Aggressive Biology in Patients with Urothelial Carcinoma of the Upper Urinary Tract. European Urology, 2010, 57, 575-581.	1.9	154
7	The Extent of Lymphadenectomy Seems to Be Associated with Better Survival in Patients with Nonmetastatic Upper-Tract Urothelial Carcinoma: How Many Lymph Nodes Should Be Removed?. European Urology, 2009, 56, 512-519.	1.9	143
8	What Is the Significance of Variant Histology in Urothelial Carcinoma?. European Urology Focus, 2020, 6, 653-663.	3.1	126
9	Clinical Outcomes of cT1 Micropapillary Bladder Cancer. Journal of Urology, 2015, 193, 1129-1134.	0.4	101
10	Risk stratification of patients with nodal involvement in upper tract urothelial carcinoma: value of lymphâ€node density. BJU International, 2009, 103, 302-306.	2.5	93
11	Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ confined urothelial carcinoma following radical nephroureterectomy. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 252-258.	1.6	88
12	Evidence-based Sex-related Outcomes After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: Results of Large Multicenter Study. Urology, 2009, 73, 142-146.	1.0	73
13	Long-Term Impact of Arsenic in Drinking Water on Bladder Cancer Health Care and Mortality Rates 20 Years After End of Exposure. Journal of Urology, 2012, 187, 856-861.	0.4	63
14	Assessment of the Minimum Number of Lymph Nodes Needed to Detect Lymph Node Invasion at Radical Nephroureterectomy in Patients With Upper Tract Urothelial Cancer. Urology, 2009, 74, 1070-1074.	1.0	58
15	Prognostic Implications of Lymphangiogenesis in Muscle-Invasive Transitional Cell Carcinoma of the Bladder. European Urology, 2008, 53, 571-580.	1.9	50
16	Upper Urinary Tract Carcinoma In Situ: Current Knowledge, Future Direction. Journal of Urology, 2017, 197, 287-295.	0.4	43
17	Epidemiology, prevention, screening, diagnosis, and evaluation: update of the ICUDâ€“SIU joint consultation on bladder cancer. World Journal of Urology, 2019, 37, 3-13.	2.2	42
18	Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer. BJU International, 2017, 119, 684-691.	2.5	36

#	Article	IF	Citations
19	Lymphovascular Invasion and Pathologic Tumor Stage Are Significant Outcome Predictors for Patients With Upper Tract Urothelial Carcinoma. Urology, 2008, 72, 364-369.	1.0	33
20	The role of FISH and cytology in upper urinary tract surveillance after radical cystectomy for bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 821-824.	1.6	33
21	Lymphangiogenesis occurs in upper tract urothelial carcinoma and correlates with lymphatic tumour dissemination and poor prognosis. BJU International, 2009, 103, 1040-1046.	2.5	28
22	Postoperative morbidity of tubeless versus conventional percutaneous nephrolithotomy: a prospective comparative study. Urological Research, 2011, 39, 477-481.	1.5	22
23	Â-H2AX level in peripheral blood lymphocytes as a risk predictor for bladder cancer. Carcinogenesis, 2013, 34, 2543-2547.	2.8	22
24	Prevalence of Chlamydia Trachomatis , Neisseria Gonorrhoeae , and Trichomonas Vaginalis Infection in Chilean Adolescents and Young Adults. Journal of Pediatric and Adolescent Gynecology, 2018, 31, 411-415.	0.7	18
25	The role of lymphangiogenesis in lymphatic tumour spread of urological cancers. BJU International, 2009, 104, 592-597.	2.5	14
26	Adaptation to Extreme Environments in an Admixed Human Population from the Atacama Desert. Genome Biology and Evolution, 2019, 11, 2468-2479.	2.5	13
27	Postadmixture Selection on Chileans Targets Haplotype Involved in Pigmentation, Thermogenesis and Immune Defense against Pathogens. Genome Biology and Evolution, 2020, 12, 1459-1470.	2.5	11
28	Topical Chemotherapy in Human Urothelial Carcinoma Explants: A Novel Translational Tool for Preclinical Evaluation of Experimental Intravesical Therapies. European Urology, 2009, 56, 504-511.	1.9	7
29	Impact of arsenic exposure on clinicopathological characteristics of bladder cancer: A comparative study between patients from an arsenic-exposed region and nonexposed reference sites. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 40.e1-40.e7.	1.6	7
30	Immediate postoperative morbidity in patients with indwelling double-J stent versus overnight-externalized ureteral catheter after tubeless percutaneous nephrolithotomy: a prospective, randomized study. Urolithiasis, 2013, 41, 253-256.	2.0	5
31	Arsenic exposure is associated with significant upper tract urothelial carcinoma health care needs and elevated mortality rates. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 638.e7-638.e13.	1.6	4
32	Additive antitumoral effect of interleukin-12 gene therapy and chemotherapy in the treatment of urothelial bladder cancer in vitro and in vivo. International Urology and Nephrology, 2011, 43, 721-727.	1.4	3
33	Long-Term Oncological and Functional Outcomes After Robot-Assisted Partial Nephrectomy for Clinically Localized Renal Cell Carcinoma. Annals of Surgical Oncology, 2022, 29, 2484-2494.	1.5	3